Chapter 16

The Ketamine and Drug-Induced Experience Objection

A. The Critic’s Argument: “It’s Just a Chemical Trip”

Imagine you are talking with a friend about near-death experiences. You describe the overwhelming peace, the sensation of floating free from the body, the tunnel of light, the encounter with deceased loved ones. Your friend listens politely, then shrugs. “You know they can produce all of that with a drug, right? It’s called ketamine. People take it recreationally and report the same things. The whole NDE is just brain chemistry.”

That, in a nutshell, is the drug-induced experience objection. It is one of the most common skeptical arguments you will hear, and it is one that has gained significant traction in both academic and popular discussions of NDEs. The argument goes like this: if a drug can produce experiences that look very much like a near-death experience, then NDEs are probably caused by chemicals in the brain. No soul required. No afterlife needed. Just neurons doing what neurons do when flooded with certain substances.

Michael Marsh devotes a significant portion of chapter 9 of his Oxford monograph to the role of ketamine, and he takes it seriously—more seriously, I think, than the evidence warrants. He treats ketamine as occupying a “paradigmatic role” for understanding the mechanisms behind what he calls extra-corporeal experiences (ECEs).¹ In his discussion, Marsh traces the neurochemistry in careful detail. Ketamine is a dissociative anesthetic, first synthesized in 1962, that works by blocking NMDA receptors (a type of receptor for the brain chemical glutamate, which is one of the main messengers that brain cells use to talk to one another).² At sub-anesthetic doses—doses lower than what a surgeon would use to put you under—ketamine produces what are called “emergence phenomena.” These can include vivid colored imagery, a feeling of timelessness, a sense of acquiring deep insight, emotional highs, and sometimes a sensation of floating outside one’s body.³

The resemblance to certain elements of the NDE is real, and Marsh does not shy away from it. He notes that the proposition that ketamine is a “dissociative paradigm” for ECEs depends on the idea that the brain may produce its own ketamine-like substance under extreme stress—an endogenous NMDA blocker that floods the brain during oxygen deprivation or seizure activity.⁴ This is essentially the model first proposed by psychiatrist Karl Jansen in a series of papers beginning in 1989, which became the most sophisticated pharmacological theory of NDEs in the literature.⁵

Jansen’s model works like this. When the brain is starved of oxygen (a condition called anoxia or hypoxia), or when it is seized by epileptic activity, the neurotransmitter glutamate gets released in dangerously high amounts. Too much glutamate kills brain cells—a process scientists call excitotoxicity. Jansen proposed that the brain has a built-in defense system: it releases a substance similar to ketamine that blocks the NMDA receptors, preventing the toxic flood of glutamate from destroying neurons. And as a side effect, this protective chemical reaction produces the vivid, otherworldly experiences that people report during NDEs.⁶ In Jansen’s own words, the endogenous ketamine-like substance would “protect the brain from excitotoxic cell damage, while generating a mental state that has valuable psychological aspects, such as holding overwhelming anxiety at bay.”⁷

Fischer and Mitchell-Yellin, in their philosophical treatment of NDEs, make a related point from a different angle. In their chapter on single-factor explanations, they note that Eben Alexander systematically considers “endogenous glutamate blockade with excitotoxicity (mimicking ketamine)” among the possible physical explanations for his own NDE, and they argue that the rejection of individual physical explanations does not mean physical explanations are irrelevant.⁸ Their broader strategy is to suggest that even if no single drug or chemical reaction explains the entire NDE, a combination of such factors might. Ketamine may explain the out-of-body sensation. Endorphins may explain the bliss. Temporal lobe activity may explain the life review. Put them all together, and you have an NDE without any need to invoke the supernatural.

The argument also extends beyond ketamine. Other substances have been brought into the conversation. Rick Strassman’s research on DMT (dimethyltryptamine)—a powerful hallucinogen found naturally in the human body—has led some to propose that the brain releases a surge of DMT at the moment of death, producing the classic NDE features.⁹ Ronald Siegel, a professor of psychopharmacology at UCLA, pointed to peyote (which contains the hallucinogen mescaline) as producing episodes that he claimed were virtually identical to NDEs.¹⁰ And as Marsh himself notes, nitrous oxide, barbiturates, and various other drugs have all been flagged as capable of producing at least some individual features of the near-death experience.¹¹

Marsh takes the ketamine connection further than many skeptics by grounding it in detailed neurochemistry. He notes that at sub-anesthetic dose levels, ketamine interferes with dopaminergic pathways in the prefrontal cortex, producing effects that resemble the metabolic hyperfrontality seen in acutely psychotic schizophrenic subjects, including ego-disintegration and hallucinations.⁵⁸ He argues that these pathways overlap significantly with the brain regions implicated in the various phenomena of the NDE—the temporal lobe, the parietal cortex, the limbic system—suggesting a common neural substrate. For Marsh, this neurological overlap is not a coincidence. It is a clue that the NDE can be traced back to identifiable brain mechanisms, and ketamine gives us a pharmacological window into those mechanisms.

Other critics have added their voices to this chorus. Susan Blackmore, in Dying to Live, argued that the dying brain produces a cascade of neurochemical events—endorphins for the bliss, random cortical firing for the tunnel and light, temporal lobe activation for the life review—and that drugs like ketamine simply trigger those same cascades artificially.⁵⁹ Gerald Woerlee, an anesthesiologist, has made similar arguments from his clinical experience, contending that the pharmacological profile of ketamine matches the NDE closely enough to establish a causal link.⁶⁰ And in popular culture, the ketamine-NDE connection has become almost an article of faith for those who want a neat, tidy, materialist explanation for what happens when people come close to death.

So the skeptical case is clear: drugs can mimic NDEs, the brain probably produces its own versions of these drugs under extreme stress, and therefore the NDE is a pharmacological event—nothing more than a chemical firework show put on by a brain fighting for survival.

It is a tidy argument. It sounds scientific. And to a casual listener, it can seem devastating.

But it isn’t. And in the pages that follow, I am going to show you exactly why.

B. Identifying Weaknesses in the Drug Argument

The drug-induced experience argument has a number of serious problems that the critics tend to skip past rather quickly. Before we build the positive case, I want to name these problems plainly. And I want to be fair about this. The drug argument is not ridiculous. It raises a genuine question. If a drug can produce some NDE-like features, that fact deserves attention and explanation. What the drug argument fails to do, however, is to provide an adequate answer to the question it raises. The resemblance between drug trips and NDEs raises a question; the skeptics treat it as though it has answered one. Those are two very different things.

The first and most fundamental problem is that resemblance is not identity. The fact that two experiences share some common features does not prove they have the same cause. This is a basic principle of reasoning that gets overlooked with surprising frequency in the NDE debate. Think about it this way. A photograph of a sunset and an actual sunset both present you with a visual experience of orange and red and gold streaking across a sky. But the photograph is ink on paper, and the actual sunset is light refracting through the atmosphere. They share features. They do not share a cause. Or consider a simpler example: a realistic dream about eating dinner is not the same as actually eating dinner, even though both involve the experience of tasting food. Similarity in the output tells you nothing definitive about the mechanism behind it.

Chris Carter, in Science and the Near-Death Experience, puts this point with admirable clarity. He notes that the most Ronald Siegel had ever shown was that several individual elements of the NDE, taken one at a time, tend to appear randomly in some psychedelic trips. What Siegel never demonstrated was that the orderly and predictable sequence of NDE elements—its core pattern—shows up consistently during drug-induced hallucinations.¹² This is a critical distinction. One of the most striking features of the NDE is the consistency of its core elements across a wide variety of people and situations. Drug hallucinations, by contrast, are highly variable. Their content depends enormously on what researchers call “set and setting”—the user’s expectations and the environment in which the drug is taken.¹³

The second weakness is that ketamine produces a much wider range of experiences than those found in NDEs, and the NDE-like subset is actually quite small. Ketamine users report seeing cartoon figures, geometric patterns, prehistoric monsters, kaleidoscopic colors, honeycombs, lattice patterns, and a host of other bizarre images that are conspicuously absent from NDE accounts.¹⁴ The NDE-like elements—mainly a sensation of being outside one’s body, sometimes with feelings of peace—appear to be a narrow subset within a much wider and stranger hallucinatory repertoire. As Carter observes, cobwebs, honeycombs, and lattices show up in hallucinations but are nowhere to be found in NDE accounts.¹⁵

Third, Marsh himself notes a significant problem that he does not fully reckon with: the troubling differences between ketamine experiences and NDEs. He acknowledges that ketamine flashbacks resemble those associated with LSD more than they resemble NDEs.¹⁶ He reports that in Barbara Collier’s large study of 131 surgical patients given ketamine, 60 percent of the sample did not wish to repeat the experience.¹⁷ And he concedes that one patient’s ketamine-induced delusion—a man who believed he had ascended to heaven, seen God, been reincarnated in Italy, and spent over two hours in the recovery room convinced he was speaking Italian—has no parallel in the NDE literature.¹⁸ These are not minor qualifications. They point to a fundamental disconnect between what ketamine actually does and what NDEs actually are.

Fourth, the endogenous ketamine hypothesis—the idea that the brain produces its own NMDA-blocking chemical during crisis—remains, at this point, entirely speculative. Marsh is honest enough to say this. He writes that the proposal depends on the notion that an endogenous NMDA blocker exists, and he admits that “at present, there seems to be little hard support for this radical, but interesting, concept.”¹⁹ He mentions agmatine, a breakdown product of L-arginine, as a possible candidate, but notes that researchers have questioned whether these substances are anything more than laboratory artifacts.²⁰ The entire ketamine model, then, hangs on a substance that has never been demonstrated to exist in the brain in the quantities or at the times required by the theory.

Fifth—and this is the problem the critics almost never address—no drug has ever been shown to produce veridical perception. This is the elephant in the room. The entire evidential case for NDEs rests not on the subjective experience of peace or tunnels or light, but on the verified, objectively confirmed reports of patients perceiving real events during clinical death that they could not have perceived through any known physical mechanism. Ketamine does not do this. DMT does not do this. No psychoactive substance in the history of pharmacology has ever been shown to give a patient accurate, verifiable knowledge of events occurring in another room.²¹ Until the drug model can account for veridical perception, it has not even begun to explain the strongest NDE evidence.

Sixth, there is the problem of the aftereffects. NDEs consistently produce deep, lasting, life-altering transformation in the experiencer: a dramatically reduced fear of death, increased empathy and compassion, a stronger sense of meaning and purpose, and often a complete reorientation of life priorities. These effects have been documented in prospective studies, confirmed in long-term follow-ups, and shown to persist for years and even decades. Drug experiences, including ketamine experiences, simply do not produce this pattern of transformation with anything approaching the same consistency or depth. Strassman himself noted that the emergence reactions from ketamine anesthesia are often unpleasant, not desired to be repeated, and lack the long-term beneficial effects that characterize the NDE.⁷² If the NDE were just a chemical event, why would it produce such profoundly different long-term outcomes from the chemical events that supposedly replicate it?

C. The Pro-NDE Response: Why the Drug Argument Fails

The Ketamine Trip Is Not an NDE

We need to get specific here, because the details matter. When people who have experienced both a ketamine trip and a genuine near-death experience are asked to compare the two, they consistently report that they are fundamentally different. This is not a minor point. It is an empirical observation that goes right to the heart of the argument.

Kenneth Ring, one of the most prominent NDE researchers in the world, took ketamine experimentally nine times. His verdict was unequivocal. In a personal communication with Chris Carter, Ring wrote that his ketamine experiences were “extremely variable,” and that while often transcendent, nothing he experienced—either in content or texture—had any particular overlap with the classic NDE.²² Ring is a careful researcher who has interviewed hundreds of NDErs. If anyone was positioned to detect a genuine resemblance between ketamine and the NDE, it was him. He did not find one.

Rick Strassman, a psychiatrist who participated directly in extensive clinical research on hallucinogenic drugs, was similarly unimpressed by the comparison between ketamine and NDEs. He noted the fearful nature of many ketamine emergence reactions—the experiences patients have as they come out of ketamine anesthesia. These emergence phenomena, he observed, while sharing some features with NDEs, are often unpleasant, not desired to be repeated, and lack the lasting transformative effects that NDEs consistently produce.²³

This point about the emotional character of the experience deserves emphasis. NDEs are overwhelmingly characterized by profound peace, clarity, and a sense of hyper-reality—the common description is that the experience felt “more real than real.” Ketamine, by contrast, frequently produces fear, confusion, disorientation, and panic. Robert Johnstone, a physician who took ketamine as part of a research study, described an experience of terror: he found himself a disembodied mind floating through bizarre locations, unable to control where he went, unable to distinguish reality from hallucination, eventually screaming “They’re after me!” and thrashing defensively.²⁴ After the experience, he dropped out of the study, feared permanent psychological damage, and refused to ever take ketamine again—or to use it as a sole anesthetic on a patient.²⁵

Does that sound like a near-death experience to you?

I have spoken with NDE researchers who have heard dozens of accounts from both ketamine users and NDErs. The verdict is consistent: the two experiences occupy different categories of human experience. The ketamine trip is disorienting, often frightening, and typically fades from memory the way dreams do. The NDE is clarifying, typically peaceful, and burns itself into the memory with a permanence that decades cannot erode. Greyson’s research has shown that NDE memories remain remarkably stable over periods of twenty years and more—unlike ordinary memories, drug memories, or confabulated memories, all of which degrade over time. If the NDE were a chemical hallucination, it should fade like one. It does not.

The contrast could hardly be more dramatic. NDE survivors consistently describe their experiences as the most real, most meaningful, most transformative event of their entire lives. They report reduced fear of death, increased compassion, and a lasting sense of purpose. Jeffrey Long’s research through the Near-Death Experience Research Foundation (NDERF) has shown that NDErs who have also experienced hallucinations and lucid dreams consistently distinguish the NDE as categorically different from any drug-induced or dream state.²⁶ The NDE is not just more vivid than a hallucination. It is experienced as a different kind of event altogether.

J. Steve Miller, in his analysis of the drug objection in Blinded by the Light, makes the same point from a slightly different angle. He notes that drug-induced experiences are extremely vague and vary considerably from person to person, while NDEs display remarkable consistency across populations regardless of age, sex, race, education, or religious background.²⁷ The pattern holds whether the NDEr is a child, an atheist, a Hindu, or a devout Christian; whether the NDE was triggered by cardiac arrest, drowning, combat injury, or surgical complication. Drug hallucinations show no such consistency. Their content is shaped by the drug, the dose, the user’s mental state, and the physical environment. NDEs are shaped by something else entirely.

Consider the testimony of Barbara Collier, whose large clinical study of ketamine is one of the most detailed in the literature. Of 131 surgical patients given ketamine, the range of reactions was enormous. Some patients felt pleasant floating sensations. Others experienced vivid and frightening hallucinations. One patient saw a file of prehistoric monsters walking. Another experienced a pastoral landscape. A third watched animated cartoons. Yet another reported waking from a vivid dream that was “still going on.”⁶¹ The most dramatic case in her study involved a man who believed he had ascended to heaven, seen God, and been reincarnated in Italy—an illusion that persisted for over two hours during which he was convinced he was speaking Italian.⁶² Now pause and compare that to the typical NDE report: peaceful, coherent, structured, with a consistent sequence of elements (OBE, tunnel, light, beings, life review, boundary, return) and no conviction of being reincarnated as an Italian speaker. The disconnect between the two types of experience is striking.

Even the subset of ketamine experiences that most closely resemble NDEs reveals significant differences upon closer inspection. In Collier’s study, eleven patients given moderate ketamine doses reported a sensation of floating in space, nine felt their spirit or mind rise from the body, and three were able to “look down” on their bodies lying on the trolley.⁶³ These are intriguing reports, but they are brief, fragmented, and lack the rich, extended narrative structure of a genuine NDE. More importantly, none of these patients reported veridical perception—none accurately described events occurring outside their field of view or in another room. The floating sensation is real. The informational content is absent. And it is the informational content—the veridical perception—that makes NDEs evidentially significant.

The Selectivity Problem

Here is another problem the drug model cannot solve, and it is a devastating one. If NDEs are caused by the brain’s release of an endogenous ketamine-like chemical during crisis, then every brain in crisis should release that chemical, and every patient who goes through that crisis should have an NDE. But they don’t.

Pim van Lommel’s landmark cardiac arrest study, published in The Lancet in 2001, found that only 18 percent of cardiac arrest survivors reported an NDE.²⁸ All of those patients experienced the same physiological crisis: their hearts stopped, their blood pressure dropped to zero, their brains were deprived of oxygen, and they lost consciousness. Every one of them underwent the same biological catastrophe. Yet more than 80 percent of them had no NDE at all. If a chemical mechanism were responsible, why the selectivity? Why don’t all dying brains produce the experience?

This selectivity problem was noted by Carter and applies to the ketamine model with particular force. If a ketamine-like substance is released automatically during anoxia as a neuroprotective mechanism, it should be released in every case of anoxia. The defense mechanism, if it exists, would not randomly decide to protect some brains and not others. And yet the vast majority of cardiac arrest patients report nothing at all—no experience, no memory, no NDE. The drug model has no answer for this.²⁹

Some skeptics try to get around this by suggesting that perhaps all patients do have some NDE-like brain activity during cardiac arrest, but most simply do not remember it afterward. This sounds plausible until you examine it more carefully. If the chemical mechanism fires in every case and produces the NDE experience, then memory failure would have to explain why 82 percent of patients remember absolutely nothing. But memory failure during cardiac arrest is precisely the problem: the brain is so compromised that it cannot form memories. If the brain is too compromised to form memories, how is it also producing the vivid, hyper-lucid, richly detailed experience that the 18 percent do remember? The skeptic cannot have it both ways. Either the brain is functioning well enough to produce the experience and encode the memory, or it is too compromised to do either. The selective amnesia explanation creates more problems than it solves.

Sam Parnia’s AWARE study data reinforces this point. In his large-scale prospective study, Parnia found that NDEs were not correlated with the specific physiological variables you would expect to predict a pharmacological event—they did not correlate with the duration of cardiac arrest, the specific medications administered, or the patient’s age.⁷³ If a chemical mechanism were responsible, these variables should matter. They did not.

Confusion Versus Clarity

There is an even deeper problem here, and it is one that Peter Fenwick, a respected neuropsychiatrist, has articulated with great precision. As he points out, any physician who deals with head injury, epilepsy, or compromised brain function knows that as the brain loses capacity, it becomes disorganized. Even in something as simple as ordinary fainting, recovery is marked by confusion. Acute cerebral catastrophes produce confusion, not clarity. This is a fundamental, well-established fact of neuroscience.³⁰

Think about what this means for the ketamine model. Jansen argues that the brain releases a ketamine-like substance when it is starving for oxygen. But a brain starving for oxygen is a brain in severe distress—a brain that, by everything we know about neuroscience, should be producing confusion, fragmented thoughts, and disorganized perceptions. What it should not be producing is the crystal-clear, hyper-lucid, coherently structured experience that NDErs consistently describe. As Fenwick puts it, although ketamine may produce experiences that share some surface features with the NDE, the model cannot explain how these experiences arise in a dysfunctional brain.³¹

Marsh seems aware of this tension. He notes that ketamine-associated dissociative episodes are emergence phenomena—they occur as subjects are emerging from the drug’s influence, regaining conscious awareness. He sees this as analogous to his broader claim that NDEs happen during recovery rather than during the deepest phase of unconsciousness.³² But this only pushes the problem back a step. A recovering brain is still a compromised brain. The period immediately before and after unconsciousness is typically marked by amnesia, not heightened lucidity. The length of that amnestic period is, in fact, one of the standard clinical measures for assessing the severity of a brain injury. How, then, do NDErs report experiences of extraordinary clarity and detail from precisely the period when their brains were least capable of producing such experiences?

The Radio Analogy: Correlation Is Not Causation

At the heart of the drug argument lies a deeper assumption that most people never stop to examine. The assumption is this: if a change in brain chemistry can alter a person’s conscious experience, then brain chemistry must produce conscious experience. But this assumption is not required by the evidence. It is added to the evidence.

Consider a radio. If you damage a radio’s receiver, the music changes. It gets distorted. It fades. It stops. Does this mean the radio was producing the music? No. The radio was receiving the music. The signal exists independently of the receiver. Damage the receiver and you damage the output, but you have not damaged the source.³³

William James made this point over a century ago in his Ingersoll Lecture at Harvard. He argued that the dependence of consciousness on the brain for the manner of its expression does not prove that consciousness depends on the brain for its existence. The brain might function as a transmitter or a filter of consciousness, not the producer of it.³⁴ James pointed out that we also find permissive and transmissive functions in nature—the trigger of a crossbow, the lens of a prism. The lens does not create the light; it channels it. The keys of an organ do not create the music; they let the air through in certain shapes.³⁵

Gary Schwartz, professor of psychology, neurology, psychiatry, medicine, and surgery at the University of Arizona, has made the same argument from a modern neuroscience perspective. He notes that the three main kinds of evidence neuroscientists use to argue that the brain produces consciousness—correlation studies, stimulation studies, and ablation studies—are exactly the same methods a technician would use when repairing a television. Damage the TV, and the picture changes. Stimulate certain circuits, and the picture changes. But no one concludes that the television is creating the broadcast. The evidence from neuroscience, Schwartz argues, is just as compatible with the hypothesis that the brain is a receiver-transmitter as it is with the hypothesis that the brain is a producer.³⁶

What does this have to do with ketamine? Everything. When ketamine blocks NMDA receptors and produces an altered state of consciousness, the materialist concludes that the drug is producing the experience by disrupting the brain’s chemistry. But on the filter/transmission model, something very different is happening. The drug is disrupting the brain’s filtering mechanism, partially releasing consciousness from its normal constraints, and allowing it to glimpse aspects of reality it is normally screened from perceiving. The drug does not create the experience. It removes a barrier. It is the difference between breaking a dam and creating a river.

Chris Carter summarizes the implications: the hypothesis that the brain works as a receiver-transmitter of consciousness has two decisive advantages over the production hypothesis. First, the production hypothesis has been challenged by data it cannot accommodate—the veridical NDE cases in which consciousness functions accurately while the brain is demonstrably non-functional. Second, the transmission hypothesis can accommodate both the ordinary facts of neuroscience (brain damage alters consciousness) and the extraordinary facts of NDE research (consciousness functions during brain shutdown).³⁷

The Veridical Evidence: The Decisive Test

This is where the drug argument collapses entirely, and I want to make this point as plainly as I can.

The strongest evidence for NDEs does not come from the subjective experiences of peace, light, or tunnels. It comes from the cases where patients accurately reported events they could not have perceived through any normal means—events that were later verified by independent witnesses. Patients who described specific conversations in waiting rooms down the hall. Patients who reported the exact placement of surgical instruments they could not have seen. Patients who identified people and objects in locations far from their unconscious bodies. These are the veridical cases documented meticulously in The Self Does Not Die, in Sabom’s prospective studies, in Holden’s analysis showing 92 percent accuracy in veridical OBE reports, and in van Lommel’s famous dentures case from The Lancet study.³⁸

No drug has ever produced veridical perception. Not ketamine. Not DMT. Not peyote. Not LSD. Not any substance in the pharmacological arsenal. Carter makes this point with admirable directness: what would be needed to support the idea that ketamine can induce a genuine separation of mind and body are reports of veridical perception during a drug-induced OBE. So far, these have been lacking.³⁹

Think about what this means. The drug model is being offered as an explanation for NDEs. But it cannot explain the single most evidentially significant feature of NDEs. It is like offering a theory of rain that explains the clouds but cannot account for the water. The veridical cases are the whole point. They are the reason the NDE debate matters. And the drug model simply has nothing to say about them.

To make this concrete, consider just a few examples. In van Lommel’s famous dentures case, a cardiac arrest patient was brought into the hospital deeply unconscious. A nurse removed the man’s dentures and placed them in the drawer of a crash cart during resuscitation. When the patient regained consciousness days later, he recognized the nurse and told her exactly where she had put his dentures—in the drawer of that specific cart, in that specific room. The man had been in deep cardiac arrest, with no measurable brain activity, at the time the nurse handled his dentures.⁶⁴ How does the ketamine model explain this? It doesn’t. It can’t.

Or consider the cases documented in The Self Does Not Die, where Rivas, Dirven, and Smit catalog over one hundred verified paranormal perceptions from NDEs. These are not vague anecdotes. They are cases with third-party verification, medical record confirmation, and testimony from multiple witnesses. In case after case, patients in cardiac arrest, under general anesthesia, or in deep coma reported specific, verifiable details about events occurring around them—details that were subsequently confirmed to be accurate.⁶⁵ The conclusion drawn by the authors of The Self Does Not Die is direct and powerful: during NDEs, people can apparently have not only conscious experiences but also paranormal experiences that cannot be explained in terms of current mainstream understanding of physical sensory functioning. People’s conscious experiences and mental abilities evidently do not depend ultimately on the functioning of their brains.⁶⁶

Miller puts it bluntly: there are no compelling reports of drug-induced experiences producing the kind of paranormal knowledge that NDErs come back with—knowledge of events and details they could not ordinarily have known.⁴⁰ For this reason alone, the pharmacological explanation cannot be considered adequate.

Jansen’s Own Change of Mind

Perhaps the most striking piece of evidence against the ketamine model comes from the man who invented it.

Karl Jansen spent years developing and defending the hypothesis that ketamine reproduces the NDE through NMDA receptor blockade. His work was cited by virtually every skeptic who wanted a chemical explanation for NDEs. But in 1997, after twelve years of studying ketamine, Jansen published a remarkable admission. In a postscript to an article in the Journal of Near-Death Studies, he wrote words that stunned the NDE research community:

“I am no longer as opposed to spiritual explanations of near-death phenomena as my article and this response to the commentaries on it would appear to suggest. Over the past two years … I have moved more toward the view put forward by John Lilly and Stanislav Grof: namely, that drugs and psychological disciplines such as meditation and yoga may render certain ‘states’ more accessible.”⁴¹

He continued: “After 12 years of studying ketamine, I now believe that there most definitely is a soul that is independent of experience. It exists when we begin, and may persist when we end. Ketamine is a door to a place we cannot normally get to; it is definitely not evidence that such a place does not exist.”⁴²

Read that again. The architect of the ketamine model of NDEs came to believe, based on twelve years of firsthand research, that ketamine is not producing a hallucination but opening a door. He concluded that the soul is real, that it is independent of the body, and that the drug is accessing something genuine rather than manufacturing something false.

Now, I want to be careful here. Jansen’s change of mind does not by itself prove that NDEs are real encounters with a transcendent realm. Scientists can be wrong in both directions. But it is deeply significant that the very researcher whose model is most frequently cited by NDE skeptics ultimately abandoned the materialist interpretation of his own data. If the man who built the strongest version of the drug argument came to believe that the drugs were opening a door rather than creating an illusion, perhaps the rest of us should pay attention.

The DMT Hypothesis and Its Problems

Before we leave the drug argument, we need to address the DMT hypothesis, which has gained considerable popular attention in recent years.

DMT (dimethyltryptamine) is a powerful hallucinogenic compound found naturally in the human body in trace amounts. Rick Strassman, who conducted FDA-approved clinical trials with DMT in the 1990s, has speculated that the pineal gland (a small structure deep in the brain, roughly the size of a grain of rice, located near the center of the brain between the two hemispheres) might release a massive surge of DMT at the moment of death, producing the NDE.⁴³ This idea captured the popular imagination and has been repeated widely, especially in documentary films and internet discussions about consciousness.

But the hypothesis faces severe problems, and they are not minor ones. First, and most fundamentally, there is no evidence that the pineal gland produces DMT in the quantities needed to produce a hallucinogenic experience. The trace amounts found naturally in the body are far below psychoactive levels. While a 2019 study did find DMT in rat brain tissue, the concentrations were extremely low, and extrapolating from rat brains to human near-death physiology involves a chain of assumptions that has not been validated.⁴⁴ Second, DMT hallucinations—like ketamine hallucinations—are wildly variable in content and depend heavily on set and setting, while NDEs are remarkably consistent across cultures, ages, and circumstances. Third, DMT trips do not produce veridical perception. No one under the influence of DMT has ever been shown to accurately report events occurring in another room or another building. Fourth, DMT is metabolized extremely rapidly by the enzyme monoamine oxidase (MAO), which means that any surge of DMT in a dying brain would be broken down almost immediately—likely within minutes, making it difficult to account for extended and detailed NDE narratives.⁴⁵ Fifth, many NDEs occur in situations where there is no reason to expect a DMT surge—such as sudden cardiac arrest where the person lost consciousness before having any awareness that death was approaching. The brain would need some kind of trigger to release the DMT, but in these sudden-onset cases, there is no time for such a trigger to operate.

It is also worth noting that Strassman himself has been careful to present his DMT hypothesis as speculation rather than established science. He has acknowledged that the hypothesis remains unproven and that the link between DMT and NDEs is, at this stage, a matter of conjecture rather than demonstrated fact. Other researchers, including Bruce Greyson, have pointed out that the entire pineal-DMT-NDE chain involves multiple unproven links, each of which would need to be established independently before the hypothesis could be considered credible.⁶⁷

The DMT hypothesis, like the ketamine model, is an interesting speculation. But it remains unproven, faces significant empirical obstacles, and cannot account for the veridical evidence.

Many NDEs Occur Without Any Drugs at All

There is one more point that needs to be made, and it is perhaps the simplest and most devastating of all. Many well-documented NDEs occurred in situations where the patient received no drugs whatsoever—not before, not during, and not after the experience.⁴⁶ Sudden cardiac arrest victims who collapse without warning, drowning victims pulled from water, accident victims who lose consciousness on impact—in case after case, the NDE occurred in a completely drug-free context.

This single fact should be enough to sink the pharmacological hypothesis as a complete explanation. If drugs cause NDEs, then NDEs should not occur when no drugs are present. But they do. Frequently. And the drug-free NDEs are indistinguishable in their features from those that occur in hospital settings where drugs may have been administered. The out-of-body component is the same. The tunnel and light are the same. The encounter with deceased loved ones is the same. The life review is the same. The boundary and the decision to return are the same. If drugs were the cause, removing the drugs should eliminate the experience. It does not.

Van Lommel’s prospective cardiac arrest study is particularly important here because it controlled for medication. All patients in the study underwent cardiac arrest—the same physiological crisis—but they were not all receiving the same medications. Van Lommel found no correlation between the type or amount of medication administered and the likelihood of having an NDE.⁶⁸ Patients who received no medication had NDEs at roughly the same rate as patients who had received various drugs. If the NDE were pharmacologically driven, we would expect to see a clear medication effect. There was none.

As Miller observes, this is perhaps the strongest argument against a pharmacological cause of the NDE.⁴⁷ The critics often conveniently overlook these cases, or they retreat to the endogenous chemical hypothesis—the brain must be producing its own drugs. But as we have already seen, this hypothesis is speculative, unproven, and faces its own devastating problems.

The Broader Pattern: Why Drug Arguments Keep Failing

If we step back and look at the big picture, a pattern emerges. Every pharmacological explanation of NDEs follows the same trajectory. A drug is identified that produces some features resembling some aspects of some NDEs. The drug is proposed as the explanation. Excitement builds. Papers are published. Then, under careful scrutiny, the explanation falls apart because the drug cannot account for the consistency of NDE content, the selectivity of NDE occurrence, the clarity of the experience in a compromised brain, the veridical elements, or the lasting transformative effects.

We have seen this pattern repeat itself again and again. In the 1970s and 1980s, the focus was on endorphins—the brain’s natural painkillers. Endorphins can produce pleasant feelings, but they do not produce structured, coherent, narratively complex experiences with veridical elements. (We addressed endorphins in more detail in Chapter 11.) In the 1980s, Ronald Siegel proposed that the NDE was essentially a hallucinogenic trip driven by the same mechanisms as drug-induced hallucinations. But as we have seen, his model never explained the consistent pattern of the NDE or its veridical features. In the 1990s, Karl Jansen proposed the ketamine model, which seemed for a time like the most promising pharmacological explanation. But Jansen himself ultimately abandoned the materialist interpretation. In the 2000s, the DMT hypothesis gained popularity but remains unproven. Each model is more sophisticated than the last, but each fails for the same fundamental reasons.

Bruce Greyson, editor of the Journal of Near-Death Studies and one of the most published NDE researchers in the world, has made a remarkable observation: without exception, every report of a large study of NDEs published in a mainstream medical journal has concluded that these phenomena cannot be explained as hallucinations.⁴⁸ He notes the irony that scientists who have done the most NDE research tend to believe that the mind is not exclusively housed in the brain, while those who regard NDEs as hallucinations by and large have not conducted any studies of the phenomena at all.⁴⁹

That is a remarkable statement, and it deserves to be read twice. The researchers who have actually studied NDEs—who have interviewed the patients, reviewed the medical records, checked the veridical claims, and published the results in peer-reviewed journals—have concluded that the drug explanation does not work. The people who still insist on the drug explanation are, by and large, the ones who have never done the research. If we are going to follow the evidence where it leads, we should probably listen to the people who have actually looked at it.

D. Counter-Objections and Responses

“But Even Partial Resemblance Shows a Neural Basis”

A skeptic might respond by saying: “Fine, ketamine doesn’t perfectly replicate the NDE. But the fact that it produces any resemblance at all shows that the brain is involved. NDEs are neural events, even if ketamine isn’t the whole story.”

This objection sounds reasonable but misses the point. No one denies that the brain is involved in the NDE. The question is how it is involved. If the brain is a receiver or filter of consciousness, then of course disrupting the brain with a drug would alter the conscious experience. Of course there would be neural correlates. The transmission model does not predict the absence of brain involvement; it predicts that brain involvement is mediating the experience, not creating it. The fact that ketamine produces some NDE-like features is perfectly consistent with the hypothesis that the drug is disrupting the brain’s filtering mechanism and partially freeing consciousness from its normal constraints. It does not prove that consciousness is a product of brain chemistry.

This is the logical error that runs through virtually all pharmacological arguments against NDEs. The argument always assumes what it is trying to prove: that the brain produces consciousness. If you start with that assumption, then drug-induced experiences look like evidence for the production model. But if you do not start with that assumption—if you hold it as a hypothesis to be tested rather than a truth to be assumed—then the drug evidence is equally compatible with the transmission model. The drugs may be opening a door, not painting a picture.

“Isn’t the Transmission Model Just Unfalsifiable Speculation?”

Fischer and Mitchell-Yellin raise a version of this objection. They argue that the radio/transmission analogy is not illuminating because we have no idea how the brain would “receive” nonlocalized consciousness. They contend that the analogy simply does not shed light on how consciousness works, because we have no mechanism for how the brain would interact with such a consciousness field.⁵⁰

This is a fair philosophical challenge, and I want to take it seriously. But there are two important responses.

First, the production model of consciousness faces exactly the same problem in reverse. We have no mechanism for how biochemical processes produce subjective, qualitative conscious experience. This is the famous “hard problem of consciousness,” identified by philosopher David Chalmers, and it remains completely unsolved. We understand how neurons fire. We understand how chemicals cross synapses. What we do not understand—and what no one has ever explained—is how any of that produces the felt quality of experience: the redness of red, the taste of coffee, the feeling of joy. If the production model gets a pass on the mechanism question, the transmission model deserves the same courtesy.⁵¹

Second, and more importantly, the transmission model has an empirical advantage that the production model lacks. The production model predicts that when the brain shuts down, consciousness should cease. The transmission model predicts that when the brain shuts down, consciousness may be released—freed from the filter. The NDE evidence, especially the veridical cases during flat-line EEG, fits the transmission model far better than the production model. A theory that accommodates the evidence should be preferred over one that contradicts it, even if neither theory can fully explain its own mechanism.⁵²

“What About the Piecemeal Strategy? Maybe Multiple Drugs and Factors Together Explain NDEs”

Fischer and Mitchell-Yellin explicitly advocate what they call a “multi-factor” approach: no single physical factor explains the whole NDE, but a combination of factors—ketamine-like chemicals, temporal lobe activity, endorphins, oxygen deprivation—might collectively account for all the pieces.⁵³

This is a more sophisticated objection, and I address it at length in Chapter 31 on the cumulative case. But a brief response is needed here. The piecemeal strategy fails because it cannot explain the combination of features in a single NDE. It is one thing to say that ketamine explains the OBE, endorphins explain the bliss, and temporal lobe activity explains the life review. It is another thing entirely to explain why a single patient, during a single episode of cardiac arrest, experiences all of these features together in a coherent, structured sequence—and also accurately perceives real events that are independently verified. The piecemeal approach can pick apart the pieces. It cannot explain how those pieces come together, every time, in the same coherent pattern, accompanied by veridical perception that no combination of drugs has ever produced.⁵⁴

There is an analogy that helps here. Imagine a skeptic who is trying to explain away a witness’s testimony in court. The witness says she saw the defendant at the scene, heard him speak, and noticed a distinctive scar on his hand. The skeptic argues: “Well, visual identification can be unreliable in poor lighting. Auditory memory is often distorted. And people often confuse one scar with another.” Each of these individual challenges might have some merit on its own. But the skeptic’s strategy of attacking each piece of evidence separately fails to account for the fact that the witness got all three details right, and they all pointed to the same person. The convergence of multiple accurate details is what gives the testimony its weight. The same is true of the NDE. It is not any single feature that is evidentially decisive—it is the convergence of all the features in a single, coherent experience that no patchwork of chemical explanations can reproduce.

Fischer and Mitchell-Yellin might respond that we do not need a unified mechanism—that a collection of distinct mechanisms, each operating independently, could coincidentally produce the full NDE pattern. But this stretches credulity past its breaking point. The NDE pattern is not random. It is strikingly consistent across tens of thousands of reported cases worldwide. The chances that multiple independent chemical mechanisms just happen to fire together, in the same order, producing the same coherent experience, with veridical elements included, are vanishingly small. At some point, the simpler explanation is the more honest one: the NDE is what it appears to be—a genuine experience of consciousness functioning apart from the body.

“NDEs That Occur During Ketamine Anesthesia Prove the Point”

One final objection deserves attention. Some researchers have pointed to cases where patients report NDE-like experiences specifically during ketamine anesthesia, arguing that these cases prove the connection. Marsh himself notes this convergence—the fact that ketamine emergence phenomena are, well, emergent, occurring as patients regain consciousness, which he sees as analogous to his broader timing argument about NDEs.⁵⁵

But Scott Rogo made a penetrating observation about these cases that deserves more attention than it has received. He noted that the NDE-like experiences under ketamine seem to be reported almost exclusively by patients in hospital settings recovering from surgery, not by recreational users. This suggests that the hospital setting itself—the awareness of possible death, the medical crisis, the vulnerability—may be shaping the content of the hallucination. The patient under ketamine who is worried about dying naturally constructs imagery related to death and survival. The drug provides the dissociative raw material; the context provides the narrative shape. But that is not an NDE. It is a ketamine hallucination interpreted through the lens of a life-threatening situation.⁵⁶

Carter makes a related observation: if a ketamine-like substance floods the brain during anoxia, then why don’t patients who experience sudden cardiac arrest—who lose consciousness before realizing what is happening—frequently report the features of ketamine hallucinations that are not found in NDEs? Where are the geometric patterns? The cartoon figures? The prehistoric monsters? The bizarre color distortions? These features are common in ketamine trips but absent from NDE accounts. The drug model cannot explain their absence.⁵⁷

“But Can’t Any Intense Experience Be Life-Changing? The Aftereffects Don’t Prove Anything”

A skeptic might grant that NDEs produce dramatic, lasting transformative effects—reduced fear of death, increased compassion, a profound sense of meaning—but argue that this does not prove the experience was real. After all, some drug experiences also produce lasting changes in outlook. Psilocybin studies at Johns Hopkins have shown measurable changes in personality openness months after a single dose.⁶⁹ Does the transformative power of an experience really prove that the experience reflected something objectively real?

This is a reasonable question, and it deserves a careful answer. The short answer is no—transformation alone does not prove objective reality. A powerful dream could change your life, and it would still be a dream. But the comparison between drug-induced transformation and NDE-induced transformation breaks down in several important ways.

First, the direction of the transformation is different. Drug-induced personality changes vary widely. Some are positive; some are deeply negative. Bad trips can produce lasting psychological trauma, PTSD-like symptoms, and existential dread. NDEs, by contrast, produce an overwhelmingly consistent pattern of positive change: reduced fear of death, increased compassion and empathy, a stronger sense of purpose, reduced materialism, and enhanced appreciation for life. Van Lommel’s long-term follow-up studies showed these effects persisting eight years after the NDE, with no signs of fading.⁷⁰ The consistency of the transformation mirrors the consistency of the experience itself—and both point toward something more than random chemical noise.

Second, and more fundamentally, the transformation argument is not the primary argument for the reality of NDEs. It is a supporting piece of evidence, not the foundation. The foundation is veridical perception. The transformation data becomes significant precisely because it is layered on top of the veridical evidence, the cross-cultural consistency, the blind NDE cases, the children’s NDEs, and the failure of every neurological explanation. No drug in history has produced all of these effects together. The transformation is one more thread in a rope that the drug model cannot cut.

Third, there is a telling asymmetry that the skeptics rarely acknowledge. Ketamine users who have pleasant trips often want to repeat the experience. NDErs almost never seek to have another NDE—not because it was unpleasant, but because the experience carried a gravity and weight that recreational drug use simply does not match. NDErs describe their experience not as a “trip” but as a homecoming, a revelation, or an encounter with ultimate reality. That language is not the language of pharmacology. It is the language of people who have been somewhere and seen something they cannot forget.⁷¹

Conclusion

The drug-induced experience objection is one of the most popular arguments against the reality of NDEs. It is also one of the weakest.

The ketamine model rests on unproven speculation about an endogenous chemical that has never been demonstrated to exist in the relevant quantities. The resemblance between ketamine trips and NDEs is superficial, limited to a small subset of ketamine effects, and consistently rejected by those who have experienced both. Ketamine produces fear, confusion, and bizarre hallucinations far more often than it produces anything resembling the peaceful, structured, coherent NDE. The drug model cannot explain the selectivity of NDEs (why only some patients in crisis have them), the clarity of the experience in a compromised brain (when brain distress should produce confusion), or the veridical perception that constitutes the strongest NDE evidence. The DMT hypothesis faces similar and additional problems. And many well-documented NDEs occurred without any drug involvement at all.

Most striking of all, Karl Jansen himself—the man who built the ketamine model—came to believe that the drug was opening a door to a genuine reality rather than manufacturing a hallucination.

The drug argument, in the end, does not explain NDEs. It explains only that certain chemicals can disrupt the brain’s normal functioning in ways that sometimes produce vaguely similar subjective states. But similarity is not identity, correlation is not causation, and no drug in the history of pharmacology has ever given a patient accurate, verified information about events they could not have perceived through normal means.

I want to be honest about what is at stake here. The drug model is attractive because it is tidy. It wraps up the mystery of NDEs in a chemical formula and tucks it away. If NDEs are just ketamine hallucinations, then we do not have to wrestle with the uncomfortable possibility that consciousness is not what we thought it was. We do not have to reconsider our assumptions about the brain, the soul, or what happens when we die. Everything stays safely within the materialist framework.

But the evidence does not cooperate. The evidence keeps pointing beyond the chemistry. It points toward patients who knew things they could not have known, who saw things they could not have seen, who came back from clinical death with information that was independently verified by medical staff. It points toward a phenomenon that cannot be reduced to molecules and receptors—not because we have not tried, but because every attempt to reduce it has failed.

As a Christian, I find this deeply significant. Scripture teaches that human beings are more than their bodies. We are body and soul, created by God, sustained by God, and destined for a resurrection that reunites the two. The NDE evidence does not replace Scripture. It does not add to the canon. But it provides powerful empirical corroboration for what the Bible has always taught: that consciousness is real, that the soul is real, and that death is not the end of awareness. The drug model asks us to believe that all of this is a chemical illusion. The evidence says otherwise.

The next chapter will turn to another skeptical objection—the timing problem. When do NDEs actually occur? Is there a window of brain activity during which the experience might be generated? We will see that this objection, like the drug objection, fails to account for the strongest evidence. But for now, the verdict on the pharmacological argument is clear: it started strong, it sounded scientific, and it collapsed under the weight of its own assumptions.

The drugs did not explain the experience. The experience, instead, explained the drugs. Ketamine may open a door. But the room behind the door was already there.